Focal Laser Photocoagulation in Non-Center Involved Diabetic Macular Edema

This study was performed to evaluate the functional and anatomic outcomes of focal macular laser photocoagulation in eyes with non-center involved macular edema (non-CI ME). Forty-nine eyes of 43 patients with non-CI ME were included. Focal macular laser photocoagulation was conducted on twenty-nine eyes of 25 patients, while 20 eyes of 18 patients with non-CI ME were followed without treatment and served as the control group. Data relating to best corrected visual acuity (BCVA; Early Treatment Diabetic Retinopathy Study) and central subfield thickness (CST), inner zone thickness (IZT), outer zone thickness (OZT), and total macular volume (TMV) as determined by optical coherence tomography (OCT) were collected and compared between the groups. At 12 months, VA decreased by a mean of 0.4 letters in the treatment group and 3.3 letters in the control group (p=0.03). Gain in VA ≥5 letters was noted in 6 (21%) of the eyes in the treatment group versus 1 (5%) eye in the control group (p=0.12). At 12 months, average IZT decreased by 22.6 microns in the treatment group and increased by 10.9 microns in the control group (p<0.001). The treatment group revealed significant reduction in CST, average OZT, and TMV as compared to the control group at 12 months (all p<0.05).Generally, focal laser photocoagulation may have more favourable visual outcomes in this specific group of diabetic patients than does observation. In addition, focal laser treatment provided better outcomes with improvement in OCT parameters as compared to the control group

Real-World Outcomes of Anti-VEGF Treatment for Neovascular Age-Related Macular Degeneration in Turkey: A Multicenter Retrospective Study, Bosphorus Retina Study Group Report No: 1

Objectives: To evaluate the real-world outcomes of intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment in neovascular age-related macular degeneration (nAMD) patients. Materials and Methods: Multicenter, retrospective, interventional, non-comparative study. The records of nAMD patients treated with an anti-VEGF agent on a pro re nata treatment regimen basis between January 2013 and December 2015 were reviewed. The patients who completed a follow-up period of 12 months were included. Primary outcome measures of this study were the visit and injection numbers during the first year. Results: Eight hundred eighty eyes of 783 patients met the inclusion criteria for the study. Mean number of visits at month 12 was 6.9±2.5 (range: 1-15). Mean number of injections at month 12 was 4.1±1.9 (range: 1-11). Mean visual acuity at baseline and months 3, 6, and 12 was 0.90±0.63 LogMAR (range: 0.0-3.0), 0.79±0.57 LogMAR (range: 0.0-3.0), 0.76±0.57 LogMAR (range: 0.0-3.0), and 0.79±0.59 LogMAR (range: 0.0-3.0), respectively. Mean central retinal thickness at baseline and months 6 and 12 was 395±153 μm (range: 91-1582), 330±115 μm (range: 99-975), and 332±114 μm (range: 106-1191), respectively. Conclusion: The numbers of visits and injections were much lower than ideal and were insufficient with the pro re nata treatment regimen

Intravitreal Ranibizumab Therapy for Choroidal Neovascularization Secondary to Pathological Myopia: 3-Year Outcomes

Objectives: The purpose of this study was to report the functional and anatomical results of intravitreal ranibizumab (IVR) injections administered for myopic choroidal neovascularization (mCNV) secondary to pathological myopia.Methods: In this retrospective study, 32 eyes of 32 mCNV patients were evaluated. After a first IVR injection, patients were followed up and treated with an as-needed monthly regime. Best-corrected visual acuity and optic coherence tomography (OCT) findings were evaluated at baseline and then monthly. The reinjection criteria were a reduction in visual acuity and/or an increase in central macular thickness measured with OCT.Results: The mean age of the patients was 57.7±14.6 years, and the mean axial length was 27.8±1.3 mm. The mean visual acuity improved significantly from 46.4±9.7 letters at baseline to 54.1±9.5 letters at the last follow-up visit (p0.05). The mean number of injections was 3.5±1.1, 2.3±0.9, and 1.7±0.8, at 12, 24, and 36 months, respectively.Conclusion: The results of this study indicated that IVR injections provided a significant long-term visual and anatomical benefit in cases of mCNV with few injectionsObjectives: The purpose of this study was to report the functional and anatomical results of intravitreal ranibizumab (IVR) injections administered for myopic choroidal neovascularization (mCNV) secondary to pathological myopia.Methods: In this retrospective study, 32 eyes of 32 mCNV patients were evaluated. After a first IVR injection, patients were followed up and treated with an as-needed monthly regime. Best-corrected visual acuity and optic coherence tomography (OCT) findings were evaluated at baseline and then monthly. The reinjection criteria were a reduction in visual acuity and/or an increase in central macular thickness measured with OCT.Results: The mean age of the patients was 57.7±14.6 years, and the mean axial length was 27.8±1.3 mm. The mean visual acuity improved significantly from 46.4±9.7 letters at baseline to 54.1±9.5 letters at the last follow-up visit (p0.05). The mean number of injections was 3.5±1.1, 2.3±0.9, and 1.7±0.8, at 12, 24, and 36 months, respectively.Conclusion: The results of this study indicated that IVR injections provided a significant long-term visual and anatomical benefit in cases of mCNV with few injection

Comparison of anterior chamber depth measurements taken with the Pentacam, Orbscan IIz and IOLMaster in myopic and emmetropic eyes

This study determined to assess the degree of agreement between anterior chamber depth (ACD) measurements obtained using three different devices and to analyse the relationship between ACD and spherical equivalent (SE) refraction

LASIK in children with hyperopic anisometropic amblyopia

PURPOSE: To evaluate the results of LASIK for hyperopia in pediatric eyes with amblyopia resulting from anisometropia

Complicated flap creation with femtosecond laser after radial keratotomy

Purpose: To report a case of laser in situ keratomileusis (LASIK) that used the Intralase femtosecond laser 14 years after radial keratotomy (RK) for residual myopic astigmatism

Corneal endothelial cell density in healthy Caucasian population

AbstractAimTo reveal the changes of corneal endothelial characteristics with aging among Caucasian population.MethodsNon-contact specular microscopy was performed in 564 eyes of 282 healthy Caucasian Turkish patients. Endothelial cell density (MCD), mean cell area (MCA), coefficient of variation (CV) in cell size, percentage of hexagonal cells, and central corneal thickness (CCT) were measured.ResultsThe mean age was 42±17.1 (6–85) years. The MCD of the population was 2732±305cell/mm2 (range, 1904–3802cell/mm2). The MCA was 368±41m2 (range, 263–522m2). The mean CV in cell size was 34±7 (range, 25–68), the mean percentage of hexagonal cells was 46±8% (range, 25–76%), and CCT was 513±39 (range, 407–623). There was statistically significantly negative correlation (p<0.05) between age and cell density, hexagonality, and pachymetry. There was statistically significant correlation (p<0.05) between age and MCA.ConclusionWe report the normal values of corneal endothelial characteristics in Caucasian Turkish eyes. Over the age of 20, the MCD of Caucasian eyes is more than the Indian and Iranian eyes and less than the Chinese eyes. Caucasian population’s cell density in under the age of 20 is 3101±268cell/mm2